Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies
Abstract
1. Introduction
2. Pathophysiology
3. Molecular Mechanisms
3.1. Lysosomal Dysfunction
3.2. Mitochondrial Dysfunction and Energy Metabolism
3.3. Chronic Inflammation and the Immune System
3.4. Endothelial Dysfunction
4. Disease-Modifying Treatment
4.1. Enzyme Replacement and Chaperone Therapies:
4.2. Substrate Reduction Therapy and Gene Therapy
5. Novel Therapies
5.1. SGLT2 Inhibitors
5.2. GLP-1 Agonists
5.3. Mineralocorticoid Antagonists
5.4. IL-6 Inhibitors
5.5. Colchicine
5.6. Future Directions
6. Conclusions
Author Contributions
Funding
Conflicts of Interest
Abbreviations
FD | Fabry disease |
ERT | Enzyme replacement therapy |
OCT | Oral chaperone therapy |
SGLT2 | Sodium-glucose cotransporter-2 |
GLP-1 | Glucagon-like peptide-1 |
MRA | Mineralocorticoid antagonist |
HFrEF | Heart failure with reduced ejection fraction |
HFpEF | Heart failure with preserved ejection fraction |
CKD | Chronic kidney disease |
T2DM | Type 2 diabetes mellitus |
AF | Atrial fibrillation |
LV | Left ventricular hypertrophy |
LGE | Late gadolinium enhancement |
References
- Brady, R.; Gal, A.; Bradley, R.; Martensson, E.; Warshaw, A.; Laster, L. Enzymatic defect in Fabry’s disease: Ceramide-trihexosidase deficiency. N. Engl. J. Med. 1967, 276, 1163–1167. [Google Scholar] [CrossRef] [PubMed]
- Biegstraaten, M.; Arngrímsson, R.; Barbey, F.; Boks, L.; Cecchi, F.; Deegan, P.B.; Feldt-Rasmussen, U.; Geberhiwot, T.; Germain, D.P.; Hendriksz, C.; et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: The European Fabry Working Group consensus document. Orphanet J. Rare Dis. 2015, 10, 36. [Google Scholar] [CrossRef] [PubMed]
- Echevarria, L.; Benistan, K.; Toussaint, A.; Dubourg, O.; Hagege, A.A.; Eladari, D.; Jabbour, F.; Beldjord, C.; De Mazancourt, P.; Germain, D.P. X-chromosome inactivation in female patients with Fabry disease. Clin. Genet. 2016, 89, 44–54. [Google Scholar] [CrossRef] [PubMed]
- Nair, V.; Belanger, E.; Veinot, J. Lysosomal storage disorders affecting the heart: A review. Cardiovasc. Pathol. 2019, 39, 12–24. [Google Scholar] [CrossRef]
- Torra, R. Renal manifestations in Fabry disease and therapeutic options. Kidney Int. Suppl. 2008, 111, S29–S32. [Google Scholar] [CrossRef]
- Tuttolomondo, A.; Pecoraro, R.; Simonetta, I.; Miceli, S.; Arnao, V.; Licata, G.; Pinto, A. Neurological complications of Anderson–Fabry disease. Curr. Pharm. Des. 2013, 19, 6014–6030. [Google Scholar] [CrossRef]
- Waldek, S.; Patel, M.; Banikazemi, M.; Lemay, R.; Lee, P. Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry registry. Genet. Med. 2009, 11, 790–796. [Google Scholar] [CrossRef]
- Mehta, A.; Clarke, J.T.; Giugliani, R.; Elliott, P.; Linhart, A.; Beck, M.; Sunder-Plassmann, G.; FOS Investigators. Natural course of Fabry disease: Changing pattern of causes of death in FOS—Fabry outcome survey. J. Med. Genet. 2009, 46, 548–552. [Google Scholar] [CrossRef]
- Güzel, T.; Çağlar, F.N.T.; Ekici, B.; Kış, M.; Öztaş, S.; Öz, A.; Gök, G.; Kolak, Z.; Akşit, E.; Sarıca, S.A.; et al. Prevalence of Fabry Disease in patients with left ventricular hypertrophy in Turkey: Multicenter study (LVH-TR subgroup analysis). Int. J. Cardiovasc. Imaging 2023, 39, 1143–1155. [Google Scholar] [CrossRef]
- Mehta, A.; Ricci, R.; Widmer, U.; Dehout, F.; Garcia de Lorenzo, A.; Kampmann, C.; Linhart, A.; Sunder-Plassmann, G.; Ries, M.; Beck, M. Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur. J. Clin. Investig. 2004, 34, 236–242. [Google Scholar] [CrossRef]
- Lobel, C.J.; Laney, D.A.; Yang, J.; Jacob, D.; Rickheim, A.; Ogg, C.Z.; Clynes, D.; Dronen, J. FDrisk: Development of a validated risk assessment tool for Fabry disease utilizing electronic health record data. J. Rare Dis. 2024, 3, 2. [Google Scholar] [CrossRef] [PubMed]
- Wanner, C.; Arad, M.; Baron, R.; Burlina, A.; Elliott, P.M.; Feldt-Rasmussen, U.; Fomin, V.V.; Germain, D.P.; Hughes, D.A.; Jovanovic, A.; et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol. Genet. Metab. 2018, 124, 189–203. [Google Scholar] [CrossRef]
- Orsborne, C.; Black, N.; Naish, J.H.; Woolfson, P.; Reid, A.B.; Schmitt, M.; Jovanovic, A.; Miller, C.A. Disease-specific therapy for the treatment of the cardiovascular manifestations of Fabry disease: A systematic review. Heart 2023, 110, 19–26. [Google Scholar] [CrossRef] [PubMed]
- Germain, D.P.; Waldek, S.; Banikazemi, M.; Bushinsky, D.A.; Charrow, J.; Desnick, R.J.; Lee, P.; Loew, T.; Vedder, A.C.; Abichandani, R.; et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J. Am. Soc. Nephrol. 2007, 18, 1547–1557. [Google Scholar] [CrossRef] [PubMed]
- Germain, D.P.; Elliott, P.M.; Falissard, B.; Fomin, V.V.; Hilz, M.J.; Jovanovic, A.; Kantola, I.; Linhart, A.; Mignani, R.; Namdar, M.; et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. Mol. Genet. Metab. Rep. 2019, 19, 100454. [Google Scholar] [CrossRef]
- Roy, A.; Cumberland, M.J.; O’Shea, C.; Holmes, A.; Kalla, M.; Gehmlich, K.; Geberhiwot, T.; Steeds, R.P. Arrhythmogenesis in Fabry Disease. Curr. Cardiol. Rep. 2024, 26, 545–560. [Google Scholar] [CrossRef]
- Roy, A.; Mansour, M.; Oxborough, D.; Geberhiwot, T.; Steeds, R. Multi-Modality Cardiovascular Imaging Assessment in Fabry Disease. Appl. Sci. 2022, 12, 1605. [Google Scholar] [CrossRef]
- Umer, M.; Kalra, D.K. Cardiac MRI in Fabry disease. Front. Cardiovasc. Med. 2023, 9, 1075639. [Google Scholar] [CrossRef]
- Sado, D.M.; White, S.K.; Piechnik, S.K.; Banypersad, S.M.; Treibel, T.; Captur, G.; Fontana, M.; Maestrini, V.; Flett, A.S.; Robson, M.D.; et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ. Cardiovasc. Imaging 2013, 6, 392–398. [Google Scholar] [CrossRef]
- Nordin, S.; Kozor, R.; Medina-Menacho, K.; Abdel-Gadir, A.; Baig, S.; Sado, D.M.; Lobascio, I.; Murphy, E.; Lachmann, R.H.; Mehta, A.; et al. Proposed Stages of Myocardial Phenotype Development in Fabry Disease. JACC Cardiovasc. Imaging 2019, 12, 1673–1683. [Google Scholar] [CrossRef]
- Nordin, S.; Kozor, R.; Baig, S.; Abdel-Gadir, A.; Medina-Menacho, K.; Rosmini, S.; Captur, G.; Tchan, M.; Geberhiwot, T.; Murphy, E.; et al. Cardiac Phenotype of Prehypertrophic Fabry Disease. Circ. Cardiovasc. Imaging 2018, 11, e007168. [Google Scholar] [CrossRef] [PubMed]
- Vijapurapu, R.; Nordin, S.; Baig, S.; Liu, B.; Rosmini, S.; Augusto, J.; Tchan, M.; Hughes, D.A.; Geberhiwot, T.; Moon, J.C.; et al. Global longitudinal strain, myocardial storage and hypertrophy in Fabry disease. Heart 2019, 105, 470–476. [Google Scholar] [CrossRef] [PubMed]
- Lu, D.Y.; Huang, W.M.; Wang, W.T.; Hung, S.C.; Sung, S.H.; Chen, C.H.; Yang, Y.J.; Niu, D.M.; Yu, W.C. Reduced global longitudinal strain as a marker for early detection of Fabry cardiomyopathy. Eur. Heart J. Cardiovasc. Imaging 2022, 23, 487–495. [Google Scholar] [CrossRef] [PubMed]
- Pieroni, M.; Chimenti, C.; Ricci, R.; Sale, P.; Russo, M.A.; Frustaci, A. Early Detection of Fabry Cardiomyopathy by Tissue Doppler Imaging. Circulation 2003, 107, 1978–1984. [Google Scholar] [CrossRef]
- Roy, A.; Thompson, S.E.; Hodson, J.; van Vliet, J.; Condon, N.; Alvior, A.M.; O’Shea, C.; Vijapurapu, R.; Nightingale, T.E.; Clift, P.F.; et al. Changes in peak oxygen consumption in Fabry disease and associations with cardiomyopathy severity. Heart 2024, 111, 230–238. [Google Scholar] [CrossRef]
- Mundigler, G.; Gaggl, M.; Heinze, G.; Graf, S.; Zehetgruber, M.; Lajic, N.; Voigtländer, T.; Mannhalter, C.; Sunder-Plassmann, R.; Paschke, E.; et al. The endocardial binary appearance (“binary sign”) is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ventricular hypertrophy. Eur. J. Echocardiogr. 2011, 12, 744–749. [Google Scholar] [CrossRef]
- Meucci, M.C.; Lillo, R.; Del Franco, A.; Monda, E.; Iannaccone, G.; Baldassarre, R.; Di Nicola, F.; Parisi, V.; Lombardo, A.; Spinelli, L.; et al. Prognostic Implications of the Extent of Cardiac Damage in Patients with Fabry Disease. J. Am. Coll. Cardiol. 2023, 82, 1524–1534. [Google Scholar] [CrossRef]
- Roy, A.; Thompson, S.E.; Hodson, J.; Win, K.Z.; Alvior, A.M.; Cumberland, M.J.; Ochoa-Ferraro, A.; Oxborough, D.; Geberhiwot, T.; Steeds, R.P. Utilitization of transthoracic echocardiography and biochemical markers in detecting cardiomyopathy in Fabry disease. CJC Open 2025, in press. [Google Scholar] [CrossRef]
- Boyd, A.C.; Lo, Q.; Devine, K.; Tchan, M.C.; Sillence, D.O.; Sadick, N.; Richards, D.A.; Thomas, L. Left atrial enlargement and reduced atrial compliance occurs early in Fabry cardiomyopathy. J. Am. Soc. Echocardiogr. 2013, 26, 1415–1423. [Google Scholar] [CrossRef]
- Moon, J.C.; Sachdev, B.; Elkington, A.G.; McKenna, W.J.; Mehta, A.; Pennell, D.J.; Leed, P.J.; Elliott, P.M. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur. Heart J. 2003, 24, 2151–2155. [Google Scholar] [CrossRef]
- Montant, P.; Sigovan, M.; Revel, D.; Douek, P. MR imaging assessment of myocardial edema with T2 mapping. Diagn. Interv. Imaging 2015, 96, 885–890. [Google Scholar] [CrossRef] [PubMed]
- Augusto, J.B.; Nordin, S.; Vijapurapu, R.; Baig, S.; Bulluck, H.; Castelletti, S.; Alfarih, M.; Knott, K.; Captur, G.; Kotecha, T.; et al. Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease. Circ. Cardiovasc. Imaging 2020, 13, e010171. [Google Scholar] [CrossRef] [PubMed]
- Nappi, C.; Altiero, M.; Imbriaco, M.; Nicolai, E.; Giudice, C.A.; Aiello, M.; Diomiaiuti, C.T.; Pisani, A.; Spinelli, L.; Cuocolo, A. First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease. Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 1025–1031. [Google Scholar] [CrossRef] [PubMed]
- Frustaci, A.; Verardo, R.; Grande, C.; Galea, N.; Piselli, P.; Carbone, I.; Alfarano, M.; Russo, M.A.; Chimenti, C. Immune-Mediated Myocarditis in Fabry Disease Cardiomyopathy. J. Am. Heart Assoc. 2018, 7, e009052. [Google Scholar] [CrossRef]
- Tøndel, C.; Bostad, L.; Hirth, A.; Svarstad, E. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am. J. Kidney Dis. 2008, 51, 767–776. [Google Scholar] [CrossRef]
- Najafian, B.; Svarstad, E.; Bostad, L.; Gubler, M.C.; Tøndel, C.; Whitley, C.; Mauer, M. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int. 2011, 79, 663–670. [Google Scholar] [CrossRef]
- Sessa, A.; Meroni, M.; Battini, G.; Maglio, A.; Brambilla, P.L.; Bertella, M.; Nebuloni, M.; Pallotti, F.; Giordano, F.; Bertagnolio, B.; et al. Renal pathological changes in Fabry disease. J. Inherit. Metab. Dis. 2001, 24 (Suppl. S2), 66–70. [Google Scholar] [CrossRef]
- Riccio, E.; Sabbatini, M.; Bruzzese, D.; Annicchiarico Petruzzelli, L.; Pellegrino, A.; Spinelli, L.; Esposito, R.; Imbriaco, M.; Feriozzi, S.; Pisani, A.; et al. Glomerular hyperfiltration: An early marker of nephropathy in Fabry disease. Nephron 2019, 141, 10–17. [Google Scholar] [CrossRef]
- Eng, C.M.; Fletcher, J.; Wilcox, W.R.; Waldek, S.; Scott, C.R.; Sillence, D.O.; Breunig, F.; Charrow, J.; Germain, D.P.; Nicholls, K.; et al. Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J. Inherit. Metab. Dis. 2007, 30, 184–192. [Google Scholar] [CrossRef]
- Schiffmann, R.; Warnock, D.G.; Banikazemi, M.; Bultas, J.; Linthorst, G.E.; Packman, S.; Sorensen, S.A.; Wilcox, W.R.; Desnick, R.J. Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. J. Inherit. Metab. Dis. 2007, 30, 184–192. [Google Scholar] [CrossRef]
- Elleder, M.; Bradová, V.; Smíd, F.; Budĕsínský, M.; Harzer, K.; Kustermann-Kuhn, B.; Ledvinová, J.; Bĕlohlávek Král, V.; Dorazilová, V. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry’s disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch. A Pathol. Anat. Histopathol. 1990, 417, 449–455. [Google Scholar] [CrossRef] [PubMed]
- Plotegher, N.; Duchen, M. Mitochondrial Dysfunction and Neurodegeneration in Lysosomal Storage Disorders. Trends Mol. Med. 2017, 23, 116–134. [Google Scholar] [CrossRef] [PubMed]
- Machann, W.; Breunig, F.; Weidemann, F.; Sandstede, J.; Hahn, D.; Köstler, H.; Neubauer, S.; Wanner, C.; Beer, M. Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A. Eur. J. Heart Fail. 2011, 13, 278–283. [Google Scholar] [CrossRef] [PubMed]
- Carosi, J.; Fourrier, C.; Bensalem, J.; Sargeant, T. The mTOR-lysosome axis at the centre of ageing. FEBS Open Bio 2022, 12, 739–757. [Google Scholar] [CrossRef]
- Sciarretta, S.; Volpe, M.; Sadoshima, J. Mammalian target of rapamycin signaling in cardiac physiology and disease. Circ. Res. 2014, 114, 549–564. [Google Scholar] [CrossRef]
- Laplante, M.; Sabatini, D. mTOR signaling at a glance. J. Cell Sci. 2009, 122, 3589–3594. [Google Scholar] [CrossRef]
- Liebau, M.C.; Braun, F.; Höpker, K.; Weitbrecht, C.; Bartels, V.; Müller, R.U.; Brodesser, S.; Saleem, M.A.; Benzing, T.; Schermer, B.; et al. Dysregulated Autophagy Contributes to Podocyte Damage in Fabry’s Disease. PLoS ONE. 2013, 8, e63506. [Google Scholar] [CrossRef]
- Nishida, K.; Kyoi, S.; Yamaguchi, O.; Sadoshima, J.; Otsu, K. The role of autophagy in the heart. Cell Death Differ. 2009, 16, 31–38. [Google Scholar] [CrossRef]
- Sanchez-Niño, M.; Carpio, D.; Sanz, A.; Ruiz-Ortega, M.; Mezzano, S.; Ortiz, A. Lyso-Gb3 activates Notch1 in human podocytes. Hum. Mol. Genet. 2015, 24, 5720–5732. [Google Scholar] [CrossRef]
- De Francesco, P.; Mucci, J.; Ceci, R.; Fossati, C.; Rozenfeld, P. Fabry disease peripheral blood immune cells release inflammatory cytokines: Role of globotriaosylceramide. Mol. Genet. Metab. 2013, 109, 93–99. [Google Scholar] [CrossRef]
- Hayashi, Y.; Hanawa, H.; Jiao, S.; Hasegawa, G.; Ohno, Y.; Yoshida, K.; Suzuki, T.; Kashimura, T.; Obata, H.; Tanaka, K.; et al. Elevated endomyocardial biopsy macrophage-related markers in intractable myocardial diseases. Inflammation 2015, 38, 2288–2299. [Google Scholar] [CrossRef] [PubMed]
- Rozenfeld, P.; Feriozzi, S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol. Genet. Metab. 2017, 122, 19–27. [Google Scholar] [CrossRef] [PubMed]
- Feriozzi, S.; Rozenfeld, P. Pathology and pathogenic pathways in Fabry nephropathy. Clin. Exp. Nephrol. 2021, 25, 925–934. [Google Scholar] [CrossRef] [PubMed]
- Alonso-Núñez, A.; Pérez-Márquez, T.; Alves-Villar, M.; Fernández-Pereira, C.; Fernández-Martín, J.; Rivera-Gallego, A.; Melcón-Crespo, C.; San Millán-Tejado, B.; Ruz-Zafra, A.; Garofano-López, R.; et al. Inflammatory and Cardiovascular Biomarkers to Monitor Fabry Disease Progression. Int. J. Mol. Sci. 2024, 25, 6024. [Google Scholar] [CrossRef]
- Martinez, P.; Aggio, M.; Rozenfeld, P. High incidence of autoantibodies in Fabry disease patients. J. Inherit. Metab. Dis. 2007, 30, 365–369. [Google Scholar] [CrossRef]
- Yogasundaram, H.; Nikhanj, A.; Putko, B.N.; Boutin, M.; Jain-Ghai, S.; Khan, A.; Auray-Blais, C.; West, M.L.; Oudit, G.Y. Elevated Inflammatory Plasma Biomarkers in Patients with Fabry Disease: A Critical Link to Heart Failure with Preserved Ejection Fraction. J. Am. Heart Assoc. 2018, 7, e00909. [Google Scholar] [CrossRef]
- Roy, A.; Umar, H.; Ochoa-Ferraro, A.; Warfield, A.; Lewis, N.; Geberhiwot, T.; Steeds, R. Atherosclerosis in Fabry Disease-A Contemporary Review. J. Clin. Med. 2021, 10, 4422. [Google Scholar] [CrossRef]
- Utsumi, K.; Yamamoto, N.; Kase, R.; Takata, T.; Okumiya, T.; Saito, H.; Suzuki, T.; Uyama, E.; Sakuraba, H. High incidence of thrombosis in Fabry’s disease. Intern. Med. 1997, 36, 327–329. [Google Scholar] [CrossRef]
- Park, J.; Whitesall, S.; D’Alecy, L.; Shu, L.; Shayman, J. Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect. Clin. Exp. Pharmacol. Physiol. 2008, 35, 1156–1163. [Google Scholar] [CrossRef]
- Rombach, S.M.; van den Bogaard, B.; de Groot, E.; Groener, J.E.; Poorthuis, B.J.; Linthorst, G.E.; van den Born, B.J.; Hollak, C.E.; Aerts, J.M. Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine. Hypertension 2012, 60, 998–1005. [Google Scholar] [CrossRef]
- Aerts, J.M.; Groener, J.E.; Kuiper, S.; Donker-Koopman, W.E.; Strijland, A.; Ottenhoff, R.; van Roomen, C.; Mirzaian, M.; Wijburg, F.A. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci. USA 2008, 105, 2812–2817. [Google Scholar] [CrossRef] [PubMed]
- Shen, J.S.; Meng, X.L.; Moore, D.F.; Quirk, J.M.; Shayman, J.A.; Schiffmann, R.; Kaneski, C.R. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol. Genet. Metab. 2008, 95, 163–168. [Google Scholar] [CrossRef] [PubMed]
- Maulik, N.; Das, D. Redox signaling in vascular angiogenesis. Free Radic. Biol. Med. 2002, 33, 1047–1060. [Google Scholar] [CrossRef] [PubMed]
- Zampetti, A.; Gnarra, M.; Borsini, W.; Giurdanella, F.; Antuzzi, D.; Piras, A.; Smaldone, C.; Pieroni, M.; Cadeddu, C.; de Waure, C.; et al. Vascular endothelial growth factor (VEGF-a) in Fabry disease: Association with cutaneous and systemic manifestations with vascular involvement. Cytokine 2013, 61, 933–939. [Google Scholar] [CrossRef]
- Rombach, S.; Hollak, C.; Linthorst, G.; Dijkgraaf, M. Cost-effectiveness of enzyme replacement therapy for Fabry disease. Orphanet J. Rare Dis. 2013, 19, 29. [Google Scholar] [CrossRef]
- Hughes, D.A.; Elliott, P.M.; Shah, J.; Zuckerman, J.; Coghlan, G.; Brookes, J.; Mehta, A.B. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: A randomised, double-blind, placebo-controlled clinical trial of Agalsidase Alfa. Heart 2008, 94, 153–158. [Google Scholar] [CrossRef]
- Mehta, A.; Beck, M.; Elliott, P.; Giugliani, R.; Linhart, A.; Sunder-Plassmann, G.; Schiffmann, R.; Barbey, F.; Ries, M.; Clarke, J.T. Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: An analysis of registry data. Lancet 2009, 374, 1986–1996. [Google Scholar] [CrossRef]
- Kampmann, C.; Perrin, A.; Beck, M. Effectiveness of Agalsidase Alfa enzyme replacement in Fabry disease: Cardiac outcomes after 10 years’ treatment. Orphanet J. Rare Dis. 2016, 11, 95. [Google Scholar] [CrossRef]
- Beck, M.; Hughes, D.; Kampmann, C.; Larroque, S.; Mehta, A.; Pintos-Morell, G.; Ramaswami, U.; West, M.; Wijatyk, A.; Giugliani, R. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis. Mol. Genet. Metab. Rep. 2015, 5, 21–27. [Google Scholar]
- Hongo, K.; Ito, K.; Date, T.; Anan, I.; Inoue, Y.; Morimoto, S.; Ogawa, K.; Kawai, M.; Kobayashi, H.; Kobayashi, M.; et al. The beneficial effects of long-term enzyme replacement therapy on cardiac involvement in Japanese Fabry patients. Mol. Genet. Metab. 2018, 124, 143–151. [Google Scholar] [CrossRef]
- Madsen, C.V.; Bundgaard, H.; Rasmussen, Å.K.; Sørensen, S.S.; Petersen, J.H.; Køber, L.; Feldt-Rasmussen, U.; Petri, H. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: A nationwide Danish cohort study. Scand. Cardiovasc. J. 2017, 51, 207–216. [Google Scholar] [CrossRef] [PubMed]
- Vijapurapu, R.; Baig, S.; Nordin, S.; Augusto, J.B.; Price, A.M.; Wheeldon, N.; Lewis, N.; Kozor, R.; Kotecha, D.; Hodson, J.; et al. Longitudinal assessment of cardiac involvement in Fabry disease using cardiovascular magnetic resonance imaging. JACC Cardiovasc. Imaging 2020, 13, 1850–1852. [Google Scholar] [CrossRef] [PubMed]
- Mignani, R.; Panichi, V.; Giudicissi, A.; Taccola, D.; Boscaro, F.; Feletti, C.; Moneti, G.; Cagnoli, L. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: A pilot study. Kidney Int. 2004, 65, 1381–1385. [Google Scholar] [CrossRef] [PubMed]
- Motwani, M.; Banypersad, S.; Woolfson, P.; Waldek, S. Enzyme replacement therapy improves cardiac features and severity of Fabry disease. Mol. Genet. Metab. 2012, 107, 197–202. [Google Scholar] [CrossRef]
- Banikazemi, M.; Bultas, J.; Waldek, S.; Wilcox, W.R.; Whitley, C.B.; McDonald, M.; Finkel, R.; Packman, S.; Bichet, D.G.; Warnock, D.G.; et al. Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann. Intern. Med. 2007, 146, 77–86. [Google Scholar] [CrossRef]
- Germain, D.P.; Charrow, J.; Desnick, R.J.; Guffon, N.; Kempf, J.; Lachmann, R.H.; Lemay, R.; Linthorst, G.E.; Packman, S.; Scott, C.R.; et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J. Med. Genet. 2015, 52, 353–358. [Google Scholar] [CrossRef]
- Weidemann, F.; Niemann, M.; Breunig, F.; Herrmann, S.; Beer, M.; Störk, S.; Voelker, W.; Ertl, G.; Wanner, C.; Strotmann, J. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: Evidence for a better outcome with early treatment. Circulation 2009, 119, 524–529. [Google Scholar] [CrossRef]
- Schiffmann, R.; Kopp, J.B.; Austin HA 3rd Sabnis, S.; Moore, D.F.; Weibel, T.; Balow, J.E.; Brady, R.O. Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 2001, 285, 2743–2749. [Google Scholar] [CrossRef]
- Warnock, D.G.; Ortiz, A.; Mauer, M.; Linthorst, G.E.; Oliveira, J.P.; Serra, A.L.; Maródi, L.; Mignani, R.; Vujkovac, B.; Beitner-Johnson, D.; et al. Renal outcomes of agalsidase beta treatment for Fabry disease: Role of proteinuria and timing of treatment initiation. Nephrol. Dial. Transplant. 2012, 27, 1042–1049. [Google Scholar] [CrossRef]
- Kim, J.H.; Lee, B.H.; Hyang Cho, J.; Kang, E.; Choi, J.H.; Kim, G.H.; Yoo, H.W. Long-term enzyme replacement therapy for Fabry disease: Efficacy and unmet needs in cardiac and renal outcomes. J. Hum. Genet. 2016, 61, 923–929. [Google Scholar] [CrossRef]
- National Institute for Health and Care Excellence. Migalastat for Treating Fabry Disease. 2016. Available online: https://www.nice.org.uk/guidance/hst4/documents/final-evaluation-determination-document#:~:text=1.1%20Migalastat%20is%20recommended%2C%20within,therapy%20(ERT)%20would%20otherwise%20be (accessed on 17 January 2025).
- Oommen, S.; Zhou, Y.; Meiyappan, M.; Gurevich, A.; Qiu, Y. Inter-assay variability influences migalastat amenability assessments among Fabry disease variants. Mol. Genet. Metab. 2019, 127, 74–85. [Google Scholar] [CrossRef] [PubMed]
- Germain, D.P.; Hughes, D.A.; Nicholls, K.; Bichet, D.G.; Giugliani, R.; Wilcox, W.R.; Feliciani, C.; Shankar, S.P.; Ezgu, F.; Amartino, H.; et al. Treatment of Fabry’s disease with the pharmacologic chaperone migalastat. N. Engl. J. Med. 2016, 375, 545–555. [Google Scholar] [CrossRef] [PubMed]
- Hughes, D.A.; Nicholls, K.; Shankar, S.P.; Sunder-Plassmann, G.; Koeller, D.; Nedd, K.; Vockley, G.; Hamazaki, T.; Lachmann, R.; Ohashi, T.; et al. Oral pharmacological chaperone Migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J. Med. Genet. 2018, 55, 422–429. [Google Scholar] [CrossRef] [PubMed]
- Radin, N.S. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj. J. 1996, 13, 153–157. [Google Scholar] [CrossRef]
- Deegan, P.B.; Goker-Alpan, O.; Geberhiwot, T.; Hopkin, R.J.; Lukina, E.; Tylki-Szymanska, A.; Zaher, A.; Sensinger, C.; Gaemers, S.J.M.; Modur, V.; et al. Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study. Mol. Genet. Metab. 2023, 138, 106963. [Google Scholar] [CrossRef]
- Idorsia Pharmaceuticals Ltd. Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects with Fabry Disease (MODIFY). 2024. Available online: https://www.clinicaltrials.gov/study/NCT03425539?tab=results (accessed on 19 January 2025).
- AceLink Therapeutics. Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males with Classic Fabry Disease. Available online: https://clinicaltrials.gov/study/NCT06114329 (accessed on 19 February 2025).
- Dave, P.; Anand, P.; Kothawala, A.; Srikaram, P.; Shastri, D.; Uddin, A.; Bhavsar, J.; Winer, A. RNA Interference Therapeutics for Hereditary Amyloidosis: A Narrative Review of Clinical Trial Outcomes and Future Directions. Cureus 2024, 16, e62981. [Google Scholar] [CrossRef]
- NICE. Overview: Vutrisiran for Treating Hereditary Transthyretin-Related Amyloidosis. Nice.org.uk. NICE. 2023. Available online: https://www.nice.org.uk/guidance/ta868 (accessed on 19 February 2025).
- Kim, I.G.; Jung, W.H.; You, G.; Lee, H.; Shin, Y.J.; Lim, S.W.; Chung, B.H.; Mok, H. Efficient delivery of globotriaosylceramide synthase siRNA using polyhistidine-incorporated lipid nanoparticles. Macromol. Biosci. 2023, 23, e2200423. [Google Scholar] [CrossRef]
- Beraza-Millor, M.; Rodríguez-Castejón, J.; Miranda, J.; del Pozo-Rodríguez, A.; Rodríguez-Gascón, A.; Solinís, M.Á. Novel golden lipid nanoparticles with small interference ribonucleic acid for substrate reduction therapy in Fabry disease. Pharmaceutics 2023, 15, 1936. [Google Scholar] [CrossRef]
- Cui, S.; Shin, Y.J.; Fang, X.; Lee, H.; Eum, S.H.; Ko, E.J.; Lim, S.W.; Shin, E.; Lee, K.I.; Lee, J.Y.; et al. CRISPR/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model. Transl. Res. 2023, 258, 35–46. [Google Scholar] [CrossRef]
- Khan, A.; Barber, D.L.; Huang, J.; Rupar, C.A.; Rip, J.W.; Auray-Blais, C.; Boutin, M.; O’Hoski, P.; Gargulak, K.; McKillop, W.M.; et al. Lentivirus-mediated gene therapy for Fabry disease. Nat. Commun. 2021, 12, 1178. [Google Scholar] [CrossRef]
- Sangamo Therapeutics. Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile. 2024. Available online: https://www.businesswire.com/news/home/20240205333085/en/Sangamo-Therapeutics-Announces-Updated-Phase-12-STAAR-Study-Data-in-Fabry-Disease-Showing-Sustained-Benefit-and-Differentiated-Safety-Profile (accessed on 19 January 2025).
- Ter Huurne, M.; Parker, B.L.; Liu, N.Q.; Qian, E.L.; Vivien, C.; Karavendzas, K.; Mills, R.J.; Saville, J.T.; Abu-Bonsrah, D.; Wise, A.F.; et al. GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals. Am. J. Hum. Genet. 2023, 110, 1600–1605. [Google Scholar] [CrossRef] [PubMed]
- Theodorakis, N.; Nikolaou, M. Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs. Biomedicines 2025, 13, 135. [Google Scholar] [CrossRef]
- Theodorakis, N.; Nikolaou, M. From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework. Biomolecules 2025, 15, 213. [Google Scholar] [CrossRef]
- Lytvyn, Y.; Bjornstad, P.; Udell, J.A.; Lovshin, J.A.; Cherney, D.Z.I. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation 2017, 136, 1643–1658. [Google Scholar] [CrossRef] [PubMed]
- Vallon, V. Renoprotective Effects of SGLT2 Inhibitors. Heart Fail. Clin. 2022, 18, 539–549. [Google Scholar] [CrossRef] [PubMed]
- Meng, Z.; Liu, X.; Li, T.; Fang, T.; Cheng, Y.; Han, L.; Sun, B.; Chen, L. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway. Int. Immunopharmacol. 2021, 94, 107492. [Google Scholar] [CrossRef]
- Zhou, H.; Wang, S.; Zhu, P.; Hu, S.; Chen, Y.; Ren, J. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol. 2024, 71, 103083. [Google Scholar] [CrossRef]
- Nakatsu, Y.; Kokubo, H.; Bumdelger, B.; Yoshizumi, M.; Yamamotoya, T.; Matsunaga, Y.; Ueda, K.; Inoue, Y.; Inoue, M.K.; Fujishiro, M.; et al. The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice. Int. J. Mol. Sci. 2017, 18, 1704. [Google Scholar] [CrossRef]
- Leng, W.; Ouyang, X.; Lei, X.; Wu, M.; Chen, L.; Wu, Q.; Deng, W.; Liang, Z. The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE−/− Mice. Mediat. Inflamm. 2016, 2016, 6305735. [Google Scholar] [CrossRef]
- Abdollahi, E.; Keyhanfar, F.; Delbandi, A.; Falak, R.; Hajimiresmaiel, S.; Shafiei, M. Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages. Eur. J. Pharmacol. 2022, 918, 174715. [Google Scholar] [CrossRef]
- McMurray, J.J.V.; Solomon, S.D.; Inzucchi, S.E.; Køber, L.; Kosiborod, M.N.; Martinez, F.A.; Ponikowski, P.; Sabatine, M.S.; Anand, I.S.; Bělohlávek, J.; et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N. Engl. J. Med. 2019, 381, 1995–2008. [Google Scholar] [CrossRef] [PubMed]
- Packer, M.; Anker, S.D.; Butler, J.; Filippatos, G.; Pocock, S.J.; Carson, P.; Januzzi, J.; Verma, S.; Tsutsui, H.; Brueckmann, M.; et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N. Engl. J. Med. 2020, 383, 1413–1424. [Google Scholar] [CrossRef] [PubMed]
- Solomon, S.D.; Vaduganathan, M.; Claggett, B.L.; de Boer, R.A.; DeMets, D.; Hernandez, A.F.; Inzucchi, S.E.; Kosiborod, M.N.; Lam, C.S.P.; Martinez, F.; et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N. Engl. J. Med. 2022, 387, 1089–1098. [Google Scholar] [CrossRef] [PubMed]
- Anker, S.D.; Butler, J.; Filippatos, G.; Ferreira, J.P.; Bocchi, E.; Böhm, M.; Brunner-La Rocca, H.P.; Choi, D.J.; Chopra, V.; Chuquiure-Valenzuela, E.; et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N. Engl. J. Med. 2021, 385, 1451–1461. [Google Scholar] [CrossRef]
- Zou, X.; Shi, Q.; Li, S. Time-Varying Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure: An Updated Meta-analysis. J. Evid.-Based Med. 2024, 17, 13–16. [Google Scholar] [CrossRef]
- Heerspink, H.J.L.; Stefánsson, B.V.; Correa-Rotter, R.; Chertow, G.M.; Greene, T.; Hou, F.F.; Mann, J.F.E.; McMurray, J.J.V.; Lindberg, M.; Rossing, P.; et al. Dapagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2020, 383, 1436–1446. [Google Scholar] [CrossRef]
- The EMPA-KIDNEY Collaborative Group; Herrington, W.G.; Staplin, N.; Wanner, C.; Green, J.B.; Hauske, S.J.; Emberson, J.R.; Preiss, D.; Judge, P.; Mayne, K.J.; et al. Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2023, 388, 117–127. [Google Scholar]
- Tsatsaronis, A.; Tiong, M.; Nicholls, K.; Ruderman, I. Sodium-glucose cotransporter 2 inhibitors reduce albuminuria in patients with Fabry disease: A real-world case series. Intern. Med. J. 2024. [Google Scholar] [CrossRef]
- Battaglia, Y.; Bulighin, F.; Zerbinati, L.; Vitturi, N.; Marchi, G.; Carraro, G. Dapaglifozin on Albuminuria in Chronic Kidney Disease Patients with FabrY Disease: The DEFY Study Design and Protocol. J. Clin. Med. 2023, 12, 3689. [Google Scholar] [CrossRef]
- Smith, N.; Hackett, T.; Galli, A.; Flynn, C. GLP-1: Molecular mechanisms and outcomes of a complex signaling system. Neurochem. Int. 2019, 128, 94–105. [Google Scholar] [CrossRef]
- Sorrenti, V.; Benedetti, F.; Buriani, A.; Fortinguerra, S.; Caudullo, G.; Davinelli, S.; Zella, D.; Scapagnini, G. Immunomodulatory and Antiaging Mechanisms of Resveratrol, Rapamycin, and Metformin: Focus on mTOR and AMPK Signaling Networks. Pharmaceuticals 2022, 15, 912. [Google Scholar] [CrossRef] [PubMed]
- Liu, T.; Zhang, L.; Joo, D.; Sun, S. NF-κB signaling in inflammation. Signal Transduct. Target. Ther. 2017, 2, 17023. [Google Scholar] [CrossRef] [PubMed]
- Alharbi, S. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther. Adv. Endocrinol. Metab. 2024, 15, 20420188231222367. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Ha, T.; Gao, X.; Kelley, J.; Williams, D.L.; Browder, I.W.; Kao, R.L.; Li, C. NF-κB activation is required for the development of cardiac hypertrophy in vivo. Am. J. Physiol. Heart Circ. Physiol. 2004, 287, H1712–H1720. [Google Scholar] [CrossRef]
- Gaspari, T.; Brdar, M.; Lee, H.W.; Spizzo, I.; Hu, Y.; Widdop, R.E.; Simpson, R.W.; Dear, A.E. Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis. Diab Vasc. Dis. Res. 2016, 13, 56–68. [Google Scholar] [CrossRef]
- Wang, C.; Li, C.; Peng, H.; Ye, Z.; Zhang, J.; Liu, X.; Lou, T. Activation of the Nrf2-ARE pathway attenuates hyperglycemia-mediated injuries in mouse podocytes. Cell. Physiol. Biochem. 2014, 34, 891–902. [Google Scholar] [CrossRef]
- Ye, Y.; Zhong, X.; Li, N.; Pan, T. Protective effects of liraglutide on glomerular podocytes in obese mice by inhibiting the inflammatory factor TNF-α-mediated NF-κB and MAPK pathway. Obes. Res. Clin. Pract. 2019, 13, 385–390. [Google Scholar] [CrossRef]
- Yu, J.; Park, S.; Lee, D.; Kim, N.; Seo, J. GLP-1 receptor agonists in diabetic kidney disease: Current evidence and future directions. Kidney Res. Clin. Pract. 2022, 41, 136–149. [Google Scholar] [CrossRef]
- Jojima, T.; Uchida, K.; Akimoto, K.; Tomotsune, T.; Yanagi, K.; Iijima, T.; Suzuki, K.; Kasai, K.; Aso, Y. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice. Atherosclerosis 2017, 261, 44–51. [Google Scholar] [CrossRef]
- Sudo, M.; Li, Y.; Hiro, T.; Takayama, T.; Mitsumata, M.; Shiomi, M.; Sugitani, M.; Matsumoto, T.; Hao, H.; Hirayama, A. Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits. Atherosclerosis 2017, 265, 283–291. [Google Scholar] [CrossRef]
- Patel, M.R.; Cecchi, F.; Cizmarik, M.; Kantola, I.; Linhart, A.; Nicholls, K.; Strotmann, J.; Tallaj, J.; Tran, T.C.; West, M.L.; et al. Cardiovascular events in patients with fabry disease natural history data from the fabry registry. J. Am. Coll. Cardiol. 2011, 57, 1093–1099. [Google Scholar] [CrossRef] [PubMed]
- Kleinert, J.; Dehout, F.; Schwarting, A.; de Lorenzo, A.G.; Ricci, R.; Kampmann, C.; Beck, M.; Ramaswami, U.; Linhart, A.; Gal, A.; et al. Prevalence of uncontrolled hypertension in patients with Fabry disease. Am. J. Hypertens. 2006, 19, 782–787. [Google Scholar] [CrossRef] [PubMed]
- Marso, S.P.; Daniels, G.H.; Brown-Frandsen, K.; Kristensen, P.; Mann, J.F.; Nauck, M.A.; Nissen, S.E.; Pocock, S.; Poulter, N.R.; Ravn, L.S.; et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2016, 375, 311–322. [Google Scholar] [CrossRef] [PubMed]
- Marso, S.P.; Bain, S.C.; Consoli, A.; Eliaschewitz, F.G.; Jódar, E.; Leiter, L.A.; Lingvay, I.; Rosenstock, J.; Seufert, J.; Warren, M.L.; et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N. Engl. J. Med. 2016, 375, 1834–1844. [Google Scholar] [CrossRef]
- Gerstein, H.C.; Colhoun, H.M.; Dagenais, G.R.; Diaz, R.; Lakshmanan, M.; Pais, P.; Probstfield, J.; Riesmeyer, J.S.; Riddle, M.C.; Rydén, L.; et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet 2019, 394, 121–130. [Google Scholar] [CrossRef]
- Perkovic, V.; Tuttle, K.R.; Rossing, P.; Mahaffey, K.W.; Mann, J.F.E.; Bakris, G.; Baeres, F.M.M.; Idorn, T.; Bosch-Traberg, H.; Lausvig, N.L.; et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N. Engl. J. Med. 2024, 391, 109–121. [Google Scholar] [CrossRef]
- Wilding, J.P.H.; Batterham, R.L.; Calanna, S.; Davies, M.; Van Gaal, L.F.; Lingvay, I.; McGowan, B.M.; Rosenstock, J.; Tran, M.T.D.; Wadden, T.A.; et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N. Engl. J. Med. 2021, 384, 989–1002. [Google Scholar] [CrossRef]
- Pi-Sunyer, X.; Astrup, A.; Fujioka, K.; Greenway, F.; Halpern, A.; Krempf, M.; Lau, D.C.; le Roux, C.W.; Violante Ortiz, R.; Jensen, C.B.; et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N. Engl. J. Med. 2015, 373, 11–22. [Google Scholar] [CrossRef]
- Kelkar, R.; Barve, N.; Kelkar, R.; Kharel, S.; Khanapurkar, S.; Yadav, R. Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: A systematic review and meta-analysis. Front. Cardiovasc. Med. 2024, 11, 1453297. [Google Scholar] [CrossRef]
- Lincoff, A.M.; Brown-Frandsen, K.; Colhoun, H.M.; Deanfield, J.; Emerson, S.S.; Esbjerg, S.; Hardt-Lindberg, S.; Hovingh, G.K.; Kahn, S.E.; Kushner, R.F.; et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N. Engl. J. Med. 2023, 389, 2221–2232. [Google Scholar] [CrossRef]
- Deanfield, J.; Verma, S.; Scirica, B.M.; Kahn, S.E.; Emerson, S.S.; Ryan, D.; Lingvay, I.; Colhoun, H.M.; Plutzky, J.; Kosiborod, M.N.; et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: A prespecified analysis of the SELECT trial. Lancet 2024, 404, 773–786. [Google Scholar] [CrossRef] [PubMed]
- Kosiborod, M.N.; Abildstrøm, S.Z.; Borlaug, B.A.; Butler, J.; Rasmussen, S.; Davies, M.; Hovingh, G.K.; Kitzman, D.W.; Lindegaard, M.L.; Møller, D.V.; et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N. Engl. J. Med. 2023, 389, 1069–1084. [Google Scholar] [CrossRef] [PubMed]
- Kosiborod, M.N.; Deanfield, J.; Pratley, R.; Borlaug, B.A.; Butler, J.; Davies, M.J.; Emerson, S.S.; Kahn, S.E.; Kitzman, D.W.; Lingvay, I.; et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: A pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet 2024, 404, 949–961. [Google Scholar] [CrossRef] [PubMed]
- Pratley, R.E.; Tuttle, K.R.; Rossing, P.; Rasmussen, S.; Perkovic, V.; Nielsen, O.W.; Mann, J.F.E.; MacIsaac, R.J.; Kosiborod, M.N.; Kamenov, Z.; et al. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial. J. Am. Coll. Cardiol. 2024, 84, 1615–1628. [Google Scholar] [CrossRef]
- Jastreboff, A.M.; Aronne, L.J.; Ahmad, N.N.; Wharton, S.; Connery, L.; Alves, B.; Kiyosue, A.; Zhang, S.; Liu, B.; Bunck, M.C.; et al. Tirzepatide Once Weekly for the Treatment of Obesity. N. Engl. J. Med. 2022, 387, 205–216. [Google Scholar] [CrossRef]
- Frías, J.P.; Davies, M.J.; Rosenstock, J.; Pérez Manghi, F.C.; Fernández Landó, L.; Bergman, B.K.; Liu, B.; Cui, X.; Brown, K. SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N. Engl. J. Med. 2021, 385, 503–515. [Google Scholar] [CrossRef]
- Chuang, M.H.; Chen, J.Y.; Wang, H.Y.; Jiang, Z.H.; Wu, V.C. Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes. JAMA Netw. Open 2024, 7, e2427258-8. [Google Scholar] [CrossRef]
- Packer, M.; Zile, M.R.; Kramer, C.M.; Baum, S.J.; Litwin, S.E.; Menon, V.; Ge, J.; Weerakkody, G.J.; Ou, Y.; Bunck, M.C.; et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N. Engl. J. Med. 2025, 392, 427–437. [Google Scholar] [CrossRef]
- Di Lullo, L.; Lavalle, C.; Scatena, A.; Mariani, M.; Ronco, C.; Bellasi, A. Finerenone: Questions and Answers-The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist. J. Clin. Med. 2023, 12, 3992. [Google Scholar] [CrossRef]
- Kuster, G.M.; Kotlyar, E.; Rude, M.K.; Siwik, D.A.; Liao, R.; Colucci, W.S.; Sam, F. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 2005, 111, 420–427. [Google Scholar] [CrossRef]
- Queisser, N.; Schupp, N. Aldosterone, oxidative stress, and NF-κB activation in hypertension-related cardiovascular and renal diseases. Free Radic. Biol. Med. 2012, 53, 314–327. [Google Scholar] [CrossRef] [PubMed]
- Bene, N.; Alcaide, P.; Wortis, H.; Jaffe, I. Mineralocorticoid receptors in immune cells: Emerging role in cardiovascular disease. Steroids 2014, 91, 38–45. [Google Scholar] [CrossRef] [PubMed]
- Barrera-Chimal, J.; Estrela, G.R.; Lechner, S.M.; Giraud, S.; El Moghrabi, S.; Kaaki, S.; Kolkhof, P.; Hauet, T.; Jaisser, F. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int. 2018, 93, 1344–1355. [Google Scholar] [CrossRef] [PubMed]
- Droebner, K.; Pavkovic, M.; Grundmann, M.; Hartmann, E.; Goea, L.; Nordlohne, J.; Klar, J.; Eitner, F.; Kolkhof, P. Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis. Am. J. Nephrol. 2021, 52, 588–601. [Google Scholar] [CrossRef]
- Grune, J.; Beyhoff, N.; Smeir, E.; Chudek, R.; Blumrich, A.; Ban, Z.; Brix, S.; Betz, I.R.; Schupp, M.; Foryst-Ludwig, A.; et al. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic Activity. Hypertension 2018, 71, 599–608. [Google Scholar] [CrossRef]
- Lavall, D.; Jacobs, N.; Mahfoud, F.; Kolkhof, P.; Böhm, M.; Laufs, U. The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling. Biochem. Pharmacol. 2019, 168, 173–183. [Google Scholar] [CrossRef]
- Solomon, S.D.; McMurray, J.J.V.; Vaduganathan, M.; Claggett, B.; Jhund, P.S.; Desai, A.S.; Henderson, A.D.; Lam, C.S.P.; Pitt, B.; Senni, M.; et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N. Engl. J. Med. 2024, 391, 1475–1485. [Google Scholar] [CrossRef]
- Pitt, B.; Filippatos, G.; Agarwal, R.; Anker, S.D.; Bakris, G.L.; Rossing, P.; Joseph, A.; Kolkhof, P.; Nowack, C.; Schloemer, P.; et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N. Engl. J. Med. 2021, 385, 2252–2263. [Google Scholar] [CrossRef]
- Bakris, G.L.; Agarwal, R.; Anker, S.D.; Pitt, B.; Ruilope, L.M.; Rossing, P.; Kolkhof, P.; Nowack, C.; Schloemer, P.; Joseph, A.; et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2020, 383, 2219–2229. [Google Scholar] [CrossRef]
- Pitt, B.; Kober, L.; Ponikowski, P.; Gheorghiade, M.; Filippatos, G.; Krum, H.; Nowack, C.; Kolkhof, P.; Kim, S.Y.; Zannad, F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial. Eur. Heart J. 2013, 34, 2453–2463. [Google Scholar] [CrossRef]
- Wang, Y.; Zhu, S.; Wei, W.; Tu, Y.; Chen, C.; Song, J.; Li, J.; Wang, C.; Xu, Z.; Sun, S. Interleukin-6 knockout reverses macrophage differentiation imbalance and alleviates cardiac dysfunction in aging mice. Aging 2020, 12, 20184–20197. [Google Scholar] [CrossRef] [PubMed]
- Khan, M.S.; Talha, K.M.; Maqsood, M.H.; Rymer, J.A.; Borlaug, B.A.; Docherty, K.F.; Pandey, A.; Kahles, F.; Cikes, M.; Lam, C.S.P.; et al. Interleukin-6 and Cardiovascular Events in Healthy Adults: MESA. JACC Adv. 2024, 3, 101063. [Google Scholar] [CrossRef] [PubMed]
- Fanola, C.L.; Morrow, D.A.; Cannon, C.P.; Jarolim, P.; Lukas, M.A.; Bode, C.; Hochman, J.S.; Goodrich, E.L.; Braunwald, E.; O’Donoghue, M.L. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial. J. Am. Heart Assoc. 2017, 6, e005637. [Google Scholar] [CrossRef] [PubMed]
- Ridker, P.M.; Devalaraja, M.; Baeres, F.M.M.; Engelmann, M.D.M.; Hovingh, G.K.; Ivkovic, M.; Lo, L.; Kling, D.; Pergola, P.; Raj, D.; et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2021, 397, 2060–2069. [Google Scholar] [CrossRef]
- Chertow, G.M.; Chang, A.M.; Felker, G.M.; Heise, M.; Velkoska, E.; Fellström, B.; Charytan, D.M.; Clementi, R.; Gibson, C.M.; Goodman, S.G.; et al. IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: A randomized phase 2b trial. Nat. Med. 2024, 30, 2328–2336. [Google Scholar] [CrossRef]
- Broch, K.; Anstensrud, A.K.; Woxholt, S.; Sharma, K.; Tøllefsen, I.M.; Bendz, B.; Aakhus, S.; Ueland, T.; Amundsen, B.H.; Damås, J.K.; et al. Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction. J. Am. Coll. Cardiol. 2021, 77, 1845–1855. [Google Scholar] [CrossRef]
- Banco, D.; Mustehsan, M.; Shah, B. Update on the Role of Colchicine in Cardiovascular Disease. Curr. Cardiol. Rep. 2024, 26, 191–198. [Google Scholar] [CrossRef]
- Itano, S.; Satoh, M.; Kadoya, H.; Sogawa, Y.; Uchida, A.; Sasaki, T.; Kashihara, N. Colchicine attenuates renal fibrosis in a murine unilateral ureteral obstruction model. Mol. Med. Rep. 2017, 15, 4169–4175. [Google Scholar] [CrossRef]
- Tardif, J.C.; Kouz, S.; Waters, D.D.; Bertrand, O.F.; Diaz, R.; Maggioni, A.P.; Pinto, F.J.; Ibrahim, R.; Gamra, H.; Kiwan, G.S.; et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N. Engl. J. Med. 2019, 381, 2497–2505. [Google Scholar] [CrossRef]
- Nidorf, S.M.; Fiolet, A.T.L.; Mosterd, A.; Eikelboom, J.W.; Schut, A.; Opstal, T.S.J.; The, S.H.K.; Xu, X.F.; Ireland, M.A.; Lenderink, T.; et al. Colchicine in Patients with Chronic Coronary Disease. N. Engl. J. Med. 2020, 383, 1838–1847. [Google Scholar] [CrossRef]
- Deftereos, S.; Giannopoulos, G.; Panagopoulou, V.; Bouras, G.; Raisakis, K.; Kossyvakis, C.; Karageorgiou, S.; Papadimitriou, C.; Vastaki, M.; Kaoukis, A.; et al. Anti-inflammatory treatment with colchicine in stable chronic heart failure: A prospective, randomized study. JACC Heart Fail. 2014, 2, 131–137. [Google Scholar] [CrossRef] [PubMed]
- Straw, S.; McGinlay, M.; Witte, K. Four pillars of heart failure: Contemporary pharmacological therapy for heart failure with reduced ejection fraction. Open Heart 2021, 8, e001585. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Thompson, S.E.; Roy, A.; Geberhiwot, T.; Gehmlich, K.; Steeds, R.P. Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies. Biomedicines 2025, 13, 624. https://doi.org/10.3390/biomedicines13030624
Thompson SE, Roy A, Geberhiwot T, Gehmlich K, Steeds RP. Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies. Biomedicines. 2025; 13(3):624. https://doi.org/10.3390/biomedicines13030624
Chicago/Turabian StyleThompson, Sophie Elizabeth, Ashwin Roy, Tarekegn Geberhiwot, Katja Gehmlich, and Richard Paul Steeds. 2025. "Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies" Biomedicines 13, no. 3: 624. https://doi.org/10.3390/biomedicines13030624
APA StyleThompson, S. E., Roy, A., Geberhiwot, T., Gehmlich, K., & Steeds, R. P. (2025). Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies. Biomedicines, 13(3), 624. https://doi.org/10.3390/biomedicines13030624